Fasoracetam

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Fasoracetam
Fasoracetam.svg
Fasoracetam3d.png
Names
IUPAC name
(5R)-5-(piperidine-1-carbonyl) pyrrolidin-2-one
Other names
(5R)-5-oxo-D-prolinepiperidinamide monohydrate, NS-105, AEVI-001, LAM 105, MDGN-001, NFC 1[1][2]
Identifiers
3D model (JSmol)
ChemSpider
KEGG
Properties
C10H16N2O2
Molar mass 196.25 g·mol−1
Pharmacology
Oral
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YesYN ?)
Infobox references

Fasoracetam is a research chemical of the racetam family.[3] It is a nootropic, and has been in clinical trials for vascular dementia and attention deficit hyperactivity disorder.[2][4]

Fasoracetam appears to agonize all three metabotropic glutamate receptors and has improved cognitive function in rodent studies.[5] It is orally available and is excreted mostly unchanged via the urine.[6]

Fasoracetam was discovered by scientists at the Japanese pharmaceutical company Nippon Shinyaku, which brought it through Phase 3 clinical trials for vascular dementia, and abandoned it due to lack of efficacy.[5][7]

Scientists at Children's Hospital of Philadelphia led by Hakon Hakonarson identified fasoracetam's potential use in attention deficit hyperactivity disorder.[5] Hakonarson started a company called neuroFix Therapeutics, LLC to try to bring the drug to market for this use; neuroFix acquired Nippon Shinyaku's clinical data as part of its efforts.[7][8] neuroFix was acquired by Medgenics in 2015.[8] Medgenics changed its name to Aevi Genomic Medicine in 2016.[9] Clinical trials in adolescents with ADHD who also have mGluR mutations started in 2016.[8]

See also[edit]

References[edit]

  1. ^ FDA/NIH Substance registration system. Page accessed March 21, 2016
  2. ^ a b "Drug Profile Fasoracetam". 
  3. ^ "5-oxo-D-prolinepiperidinamide monohydrate - Compound Summary". Retrieved 21 July 2013. 
  4. ^ "Recommended INN List 40" (PDF). WHO Drug Information. 12 (2). 1998. 
  5. ^ a b c Connolly, J; Glessner, J; Kao, C; Elia, J; Hakonarson, H. "ADHD & Pharmacotherapy: Past, Present and Future: A Review of the Changing Landscape of Drug Therapy for Attention Deficit Hyperactivity Disorder.". Ther Innov Regul Sci. 49(5): 632–642. PMC 4564067Freely accessible. PMID 26366330. doi:10.1177/2168479015599811. 
  6. ^ Malykh, AG; Sadaie, MR (12 February 2010). "Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.". Drugs. 70 (3): 287–312. PMID 20166767. doi:10.2165/11319230-000000000-00000. 
  7. ^ a b Moskowitz, D. H. (2017). Finding the Genetic Cause and Therapy for ADHD, Autism and 22q. BookBaby (self published). ISBN 9781483590981. 
  8. ^ a b c Sharma, B. "Medgenics: NFC-1 Could Be A Key Future Revenue Driver.". 
  9. ^ "Press Release: Medgenics, Inc. Announces Name Change to Aevi Genomic Medicine, Inc.". Aevi via MarketWired. 16 December 2016.